Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06HSC
|
||||
| Former ID |
DNC007651
|
||||
| Drug Name |
Folate gamma-L-phenylalaninehydroxamic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H29N9O7
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CC(C(=O)NO)NC(=O)CCC(C(=O)O)NC(=O)C2=CC=C(<br />C=C2)NCC3=CN=C4C(=N3)C(=O)N=C(N4)N
|
||||
| InChI |
1S/C28H29N9O7/c29-28-35-23-22(26(41)36-28)32-18(14-31-23)13-30-17-8-6-16(7-9-17)24(39)34-19(27(42)43)10-11-21(38)33-20(25(40)37-44)12-15-4-2-1-3-5-15/h1-9,14,19-20,30,44H,10-13H2,(H,33,38)(H,34,39)(H,37,40)(H,42,43)(H3,29,31,35,36,41)/t19-,20-/m0/s1
|
||||
| InChIKey |
WYBGJFMKGROIBY-PMACEKPBSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Matrilysin | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Wnt signaling pathway | ||||
| NetPath Pathway | Wnt Signaling Pathway | ||||
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Wnt signaling pathway | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | ||||
| p75(NTR)-mediated signaling | |||||
| Syndecan-1-mediated signaling events | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| WikiPathways | Wnt Signaling Pathway and Pluripotency | ||||
| Activation of Matrix Metalloproteinases | |||||
| AGE/RAGE pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. Epub 2006 Nov 14.Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.